Mexico lets altruistically donated plasma be transferred to private fractionators in exchange for medicines; plasma may "under no circumstances" be collected for industry
Translated from the Spanish original.
On November 2, 2026, the Secretaría de Salud (Health Ministry) published in the DOF (Mexico's federal gazette) the guidelines for the disposition of residual plasma, which take effect thirty business days later and regulate the January 2026 amendment to the Ley General de Salud (General Health Law). They allow a public blood bank, through an agreement, or a private one, through a contract, to deliver the plasma left over from donations to a legal entity that manufactures plasma-derived products in exchange for "the in-kind benefit obtained from its disposition": the agreement sets the medicines and "the quantity to be returned based on the volume of residual plasma delivered". The plasma "shall not be exchanged for economic remuneration", and the donor's consent must state that it may be industrialized "on a non-profit basis by the Blood bank that obtains them". The medicines return through hospital pharmacies whose licenses must include "the line of sale or supply" of plasma-derived products. At the same time, article 7 provides that "under no circumstances" shall donations be promoted, "including exclusive plasma donation by apheresis, for specific industrialization purposes".
Strategic interpretation
Systemic: Plasma is the raw material for albumin, immunoglobulins and clotting factors, and the guidelines open a circuit turning leftover donated plasma into those medicines without paying for it. The poles: the principle of altruistic, non-profit donation, required of donor and blood bank, and an industrial circuit where the fractionator and pharmacy operate at market value on what was donated. Second tension: the rule expressly bans dedicated apheresis, the route that yields plasma in volume elsewhere, and bets everything on leftovers. The fractionator with approved good practices and the private blood bank with volume win; the donor gets nothing and cannot know what value they generated. Consequence: It falls to the Centro Nacional de la Transfusión Sanguínea (national transfusion center), which must weigh in on each agreement; to COFEPRIS (health regulator); to the blood banks of IMSS, ISSSTE (social security institutes) and the states; to private blood banks and their hospitals; and to patients with immunodeficiencies and hemophilia who depend on plasma derivatives. What follows: the value of residual plasma is split between fractionator and dispenser, and the public system gets medicine in kind on the terms it negotiates. Hence, in 3 to 10 years, plasma may become a strategic resource with its own regime, and if leftovers fall short, pressure to open dedicated apheresis will collide with the altruistic principle that prohibits it today. Worldview: That the donor's altruism and the medicines market can coexist as long as money does not touch the moment of donation. What to watch: The public list of establishments with a favorable technical opinion from the transfusion center; the first IMSS and ISSSTE agreements with fractionators, and whether fractionation happens in Mexico or abroad; whether a private blood bank turns up selling returned plasma derivatives; and, in ten years, whether anyone proposes opening apheresis with donor compensation.
Diario Oficial de la Federación (DOF, Mexico's federal gazette), November 2, 2026: guidelines for the disposition of residual plasma, Secretaría de Salud (Health Ministry). Opened in the main thread on November 3, 2026; definitions, articles 5, 7, 17 and 19 and transitory articles were read and are quoted directly. Whether national fractionation capacity exists and the volume of imported plasma-derived products were not verified: the signal asserts neither.
Chapter signal radar
Published on November 3, 2026